SYNTHOS RESEARCH

Lam Research LRCX

Technology · Semiconductors · Synthos Deep Dive · 2026-07-03

$351.41
Hold
Risk 7Growth 8Exponential 5Fair value $300 $185–$370

At a glance

VerdictHold — systematic Synthos tier
Price (2026-07-01)$351.41 · market cap ~$439B · −10.2% on the day
Synthos scores (0–10)Downside Risk 7 · Growth Quality 8 · Exponential Potential 5
Synthos fair value (base case)~$300−15% · full range $185 (bear) – $370 (bull)
Street consensus$361 (high $500 / low $275; 39 Buy · 10 Hold · 1 Sell) — context, not our anchor
Valuation66× trailing EPS · 62× FY26E · 44× FY27E · 35× FY28E · 27× FY30E · EV/S 20× · EV/EBITDA 55×
Exponential Potential5/10 · Moderate — AI-driven WFE upcycle is real, but at $439B and inside a cyclical industry the multibagger is capped
TechnicalsExtended uptrend — $351, −19% off 52-wk high after a −10% day, above 50/200-DMA, RSI 48, +263% 12-mo (SPY +21%)
ConvictionLow-Moderate — only 3 net-bullish voices, 7 claims, and one voice is a bearish technician
Position sizingIf owned, satellite ≤2%; most investors should wait for a better entry
Next catalyst2026-07-29 FQ4'26 earnings (Street EPS $1.68, rev ~$6.65B)
Single biggest riskCyclical WFE downturn + multiple de-rate from a 66× trailing starting point

One-line thesis. Lam is a genuinely elite, oligopoly semiconductor-equipment franchise riding a real AI-driven capex wave (FY-ending-June-25 revenue $18.4B, 50% gross margin, 66% ROE, net cash) — but after a +263% twelve-month run the stock trades at 66× trailing earnings and sits above our base-case fair value, so the verdict is Watch, not Buy: the quality is not in question, the entry price is.

◆ Synthos call — Hold LRCX is a solid business largely reflected at ~$300 — fine to keep, no reason to chase; it gets interesting again below ~$255.
Downside Risk (lower = safer)
7/10 · High
Net-cash balance sheet, but 66× trailing after +263% in 12 mo, beta 1.87, and deep WFE cyclicality.
Growth Quality
8/10 · Very High
~19.5% fwd revenue CAGR / ~26% fwd EPS CAGR, 50% gross margin, 66% ROE, oligopoly moat.
Exponential Potential
5/10 · Moderate
AI-driven WFE upcycle is real optionality, but $439B cap + cyclicality cap the multibagger.
⚖ Reverse-DCF cross-check Market-implied growth ≈ 38%/yr To justify today’s $351, earnings would have to compound roughly 38% a year for 10 years (9% discount rate). Analysts forecast ~-9%/yr, so the market is pricing in MORE than what the Street expects.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

Lam Research makes the machines that make computer chips — the etching and deposition tools every big chip factory (TSMC, Samsung, Micron, Intel) has to buy to build advanced memory and AI processors. It is one of only a handful of companies on earth that can make this gear, so it earns fat profits: it keeps about 31 cents of every sales dollar as pure profit and has more cash than debt.

The catch: the stock has tripled in the last year and now trades at a very high price relative to its earnings. You would be buying a great company at a stretched price — and this is a boom-and-bust industry where chip factories slam the brakes on spending in downturns. Our verdict is Watch: keep it on your list, but the price today does not give you a margin of safety. The stock fell 10% in a single day just as we published — a reminder of how fast this one moves.

Here's what our three scores mean in everyday terms:

The one big worry: semiconductor equipment spending goes in cycles. When chipmakers pause, Lam's revenue can fall fast — and from a 66× starting price, the stock would fall further.


Price & moving averages 12 months · 50 & 200-day averages · 52-week range

50153256359462Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2652w hi $433Price 35150-DMA 321200-DMA 22352w lo $95

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

56158260362464Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2620-day avg 369Price 351

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

705030Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26RSI 48.4

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 48.

MACD 12 / 26 / 9 · trend & momentum

0Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26signal 24.0MACD 21.0

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago

69168267367466Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26LRCX 356XLK (sector) 142S&P 500 120

Solid = LRCX · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

013253851$14BFY23EPS $26$16BFY24EPS $3$18BFY25EPS $4$23BFY26EEPS $6$31BFY27EEPS $8$36BFY28EEPS $10$41BFY29EEPS $11$45BFY30EEPS $13

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$351.41
Market cap$439B
P/E trailing15×
P/E FY26E / FY27E62× / 43×
EV / Sales20.2×
EV / EBITDA54.9×
Gross margin50.0%
Net margin30.9%
Dividend yield0.30%
Beta1.868
52-wk range$95 – $433
RSI(14)48
50 / 200-DMA$321 / $223
12-mo return+263% (SPY +21%)
Street target$361 ($275–$500)
Analyst grades39 Buy · 10 Hold · 1 Sell
FMP ratingB+
Next earnings2026-08-05

What the experts actually said 7 traceable claims on LRCX · showing the highest-conviction voices

“Good long-term hold despite being frothy; won't sell a decade-long 700%+ winner just because it's run up.”
Invest Like the Bestbullishconviction 652026-04-29invest_like_the_best-8hHFrzLXIbo:cf709923f0
“Best S&P performer of early 2026 and a best-stocks-of-2025 write-up; the winning trend continues into the new year.”
Compound And Friendsbullishconviction 552026-01-02compound_and_friends-TLMfVxCP5-U:e8c0d9c540
“AI-driven demand is reshaping the semiconductor industry; Lam's investments and execution velocity are generating momentum and driving outperformance during this critical growth phase.”
Lrcx Mgmtmanagementconviction 782026-04-22LRCX-earnings-2026Q2:2ba5221440
“Lam Research is stretched—up ~30% in three weeks with high stochastics; due for a pullback.”
Brent Johnsonbearishconviction 652026-01-11brent_johnson-lXidpA90QK8:437986a439

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

Lam Research (Nasdaq: LRCX) is a Fremont, California maker of wafer-fabrication equipment (WFE) — the deposition, etch, and clean tools used to build integrated circuits. Founded 1980, ~18,600 employees, CEO Timothy Archer. Its product families (ALTUS, SABRE, VECTOR, Striker for deposition; Flex, Kiyo, Syndion, Versys for etch; the SP/EOS clean lines; Metryx metrology) sit at the heart of the most capital-intensive step in the economy: turning silicon wafers into chips. Fiscal year ends in late June.

Lam's franchise is levered to two secular drivers the panel keeps citing: (1) memory (DRAM/NAND) intensity — Lam is dominant in the etch and deposition steps that scale with 3D NAND layer counts and advanced DRAM; and (2) the AI compute buildout, which is pulling forward WFE demand and high-bandwidth-memory capacity.

Revenue mix (FY2025, from filings):

2. The expert thesis — the panel is thin and split (traceable)

Honesty first: LRCX has shallow coverage in the Synthos KB — 7 total claims across just 3 net-bullish voices, and one of those voices is bearish. This is not a high-conviction, deep-panel name like our flagship healthcare positions. The verdict here is primarily fundamentals- and quant-driven, with the sparse expert commentary used only as directional color. Every claim below reconciles to a real claim_id.

The bullish threads:

The cautionary voice:

Honest composite note. Two of the three bullish claims are momentum/hold-the-winner calls that concede the stock is frothy, and the third is management. There is no deep fundamental-valuation bull in this panel arguing the stock is cheap. That absence is itself signal — it aligns with our own math (§6) that the stock has run ahead of value.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score0–10The read
Downside Risk (lower = safer)7 · ElevatedNet-cash balance sheet (net debt −$1.6B) is a genuine offset, but 66× trailing after +263%/12-mo, beta 1.87, and deep WFE cyclicality make the stock risky even though the company is sturdy.
Growth Quality8 · Very High~19.5% fwd revenue CAGR, ~26% fwd EPS CAGR, 50% gross margin, 66% ROE / 43% ROIC, oligopoly moat — elite economics; docked from 9 only by cyclicality.
Exponential Potential5 · ModerateThe AI-WFE upcycle is real optionality, but growth decelerates after FY27 and a $439B cap inside a cyclical industry limits the multibagger.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.

CaseKey assumptionsFair value
BullAI-WFE upcycle runs hotter and longer; memory intensity + China resilient. FY28E EPS beats toward ~$10.85 (high est); market keeps paying a premium ~34×.~$370 (+5%)
Base (our anchor)Estimates roughly hit — anchor to FY28E EPS ~$9.94 (the earnings power ~2 years out that today's price leans on); a quality-but-cyclical WFE leader earns a ~30× multiple.~$300 (−15%)
BearWFE cycle rolls over / China export controls tighten; FY27E EPS ~$8.08 and the multiple de-rates to ~18–20× as the market re-prices cyclicality.~$185 (−47%)

Synthos fair value = the base case, ~$300 (−15%), with the full $185–$370 span as the honest range. Our base sits below both the current $351 price and the Street's $361 consensus — we are more cautious because we anchor to defensible out-year earnings times a normal (not peak) multiple, and we take semi-cap cyclicality seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures. Note the range is skewed: modest upside, meaningful downside — the definition of a Watch.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). LRCX is a high-quality cyclical compounder near the top of a cycle, not a fresh exponential:

Exponential Potential: Moderate (5/10). Own it, if at all, for durable ~20% earnings compounding through the cycle plus AI optionality — not for a fast multibagger from a post-triple, top-of-cycle starting price.

5. Financials (real numbers — FMP annual/quarterly)

6. Valuation — priced in or room?

There is no way to call LRCX cheap. It trades at 66× trailing EPS, 20× sales, and 55× EV/EBITDA after tripling in a year — multiples that historically mark cycle peaks for semi-cap equipment, not entry points. The bull's only defense is that EPS grows into the multiple: on live consensus the forward P/E compresses to 62× (FY26E) → 44× (FY27E) → 35× (FY28E) → 27× (FY30E) — but even the FY28E 35× is a full multiple for a cyclical, and it requires two more years of flawless execution just to justify today's price.

Anchoring honestly: apply a generous-but-normal ~30× to FY28E EPS ($9.94) and you get ~$300 — below the current $351. Apply a mid-cycle 22–26× EV/EBITDA to FY27–28E EBITDA and the implied price is ~$180–250. The math says the stock is discounting a best-case, no-downturn path. Street targets (context): consensus $361, high $500, low $275, median $333 — a wide spread that itself signals low agreement. Our ~$300 base is below consensus because we refuse to underwrite a peak multiple on peak earnings. Not a value buy, and — unlike a quality-compounder-at-full-price — not clearly a growth-into-it buy either at $351. It is a wait-for-a-pullback name.

7. Technicals (from the tech block)

8. Moat & competitive position

Lam's moat is oligopoly + switching costs + installed base. WFE is a rational few-player market: for etch and deposition, Lam competes chiefly with Applied Materials and Tokyo Electron, with ASML dominating a separate step (lithography) and KLA dominating metrology/inspection. Once a Lam tool is qualified into a customer's process flow, ripping it out means re-qualifying an entire node — enormous switching costs — and the 38%-of-revenue recurring service/spares base compounds off a growing installed footprint. R&D at 11% of sales sustains the technology lead as memory scales (3D NAND layer counts, advanced DRAM) and as AI pulls WFE intensity higher.

Peer set (FMP-supplied, market cap): Applied Materials $479B (the closest comp), KLA $308B, Micron $1.10T (a key customer, memory), Intel $605B (customer), Arm $335B, Qualcomm $186B, Texas Instruments $267B, Arista $201B, Intuit $75B, Uber $152B. (FMP's peer list is a Nasdaq-100 semis/tech grab-bag; the analytically relevant comps are AMAT and KLA — both also richly valued in this AI-capex tape.)

Structural risk to the moat: ~34% of revenue is China, exposed to tightening US export controls that can strand demand overnight.

9. Management, capital allocation & guidance

10. Catalysts & what to watch

Thesis tripwires (what would change the call to Buy or Avoid): a durable pullback toward the rising 50-DMA (~$321) or into the $250s with the AI-WFE demand thesis intact would open a Buy — Tactical window; conversely, a China export-control shock or two quarters of WFE booking declines would push toward Avoid.

11. Key risks

12. Verdict, position sizing & monitoring

Watch. LRCX is a genuinely elite, oligopoly semiconductor-equipment franchise (50% gross margin, 66% ROE, 29% FCF margin, net cash) riding a real AI-driven WFE upcycle — the business deserves a place on any quality watchlist. But the stock has tripled in a year, trades at 66× trailing / 55× EV/EBITDA, and sits above our base-case fair value of ~$300 and even a touch below the Street's $361. The panel that likes it explicitly calls it "frothy," the one bearish voice called the exact pullback that hit on publish day, and a director sold into the high. That combination — superb company, stretched price, thin conviction, deep cyclicality — is the textbook definition of a Watch, not a Buy.


Provenance & disclosures